Nishant Agrawal to Cell Line, Tumor
This is a "connection" page, showing publications Nishant Agrawal has written about Cell Line, Tumor.
Connection Strength
0.219
-
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
Score: 0.040
-
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004 Oct 19; 101(42):15172-7.
Score: 0.039
-
A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. Neuro Oncol. 2024 Oct 03; 26(10):1895-1911.
Score: 0.039
-
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. Oral Oncol. 2024 Feb; 149:106688.
Score: 0.037
-
Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Res. 2019 08 15; 79(16):4026-4041.
Score: 0.027
-
Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics. 2014 Jul; 9(7):1031-46.
Score: 0.019
-
S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol. 2005 Jul; 7(7):665-74.
Score: 0.010
-
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A. 2003 Dec 09; 100(25):15083-8.
Score: 0.009